U.S. Stock Market Midday Update: China SXT Pharmaceuticals rises 11.72%, trading volume surges, market activity attracts attention

U.S. Stock Market Midday Update China SXT Pharmaceuticals rose 11.72%, with increased trading volume and no significant news recently. The trading is active, and the capital flow is evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. Stocks with High Trading Volume in the Industry Eli Lilly fell 1.32%, with increased trading volume. Based on recent key news: On December 15, Eli Lilly initiated a Phase III clinical trial for Eloralintide, aimed at assessing its efficacy and safety for obese patients with type 2 diabetes. This move may affect market expectations for its future product line, leading to stock price fluctuations. Source: Zhitong Finance On December 15, Bank of America lowered Eli Lilly's target price from $128.60 to $126.80, reflecting the market's cautious attitude towards its short-term profitability, directly impacting the stock price decline. Source: Zhitong Finance On December 16, despite Eli Lilly's strong performance over the past five years, analysts believe other stocks are more attractive, which may weaken investor confidence in Eli Lilly. Source: Benzinga The market holds a cautious attitude towards Eli Lilly's future product line. Pfizer fell 4.48%. Based on recent news: On December 16, Pfizer disclosed that its revenue for 2025 is expected to be around $62 billion, with projected revenue for 2026 between $59.5 billion and $62.5 billion, and adjusted EPS of $2.80 to $3.00, below Wall Street expectations, leading to a stock price decline. Source: Reuters On December 16, BMO Capital Markets analysts pointed out that Pfizer plans to reinvest the $500 million cost savings into R&D, but these initiatives have not yet achieved sufficient success, with Wall Street analysts predicting that sales will remain flat or decline at least until 2031. Source: BMO Capital Markets On December 17, as U.S.-China trade tensions escalated, the U.S. stock market faced revenue challenges for Pfizer and risks of economic slowdown, further pressuring the stock price. Source: Daily Economic News The global pharmaceutical industry faces a patent cliff and intensified competition. Merck rose 2.10%, with increased trading volume. Based on recent key news: On December 16, Merck announced the issuance of $1.75 billion in convertible senior notes, with an initial conversion price of $148.20, a 22.5% premium over the last closing price. This move aims to raise funds for stock buybacks, driving the stock price up. On December 15, Merck plans to use approximately $1.3 billion of the net proceeds for stock buybacks and expects to complete this plan by the end of the first quarter of 2026. This plan enhances market confidence in the company's stock, leading to a price increase. On December 16, analyst ratings showed that out of 19 analysts, 14 rated it as "strong buy" or "buy," with a median target price of $160. Analysts' positive evaluations further supported the stock price increase. The overall industry performance is poor, with significant macroeconomic pressures Stocks Ranked Among the Top by Market Capitalization Johnson & Johnson fell 2.15%, with increased trading volume. Based on recent key news: On December 15, Johnson & Johnson was ordered to pay $40 million in a talc cancer case. This ruling raised market concerns about the company's potential legal liabilities, leading to a decline in stock price. On December 15, Johnson & Johnson's Akeega drug received FDA approval for the treatment of prostate cancer. Although this news is favorable for the company's long-term development, it failed to immediately boost the stock price. On December 16, Bank of America Securities raised Johnson & Johnson's target price to $220, maintaining a "Neutral" rating. Analysts remain cautious about the company's prospects, which did not significantly impact the stock price. The pharmaceutical industry faces regulatory and legal risks